# CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction

> **NCT06480968** · PHASE1 · COMPLETED · sponsor: **Connecta Therapeutics, S.L.** · enrollment: 76 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** CTH120
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06480968
- **Lead sponsor:** Connecta Therapeutics, S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-23
- **Primary completion:** 2024-11-11
- **Final completion:** 2024-11-11
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-01-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06480968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06480968, "CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06480968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*